NCT06558188PHASE4RecruitingAccepts Healthy Volunteers

Combined Anabolic Therapy

Massachusetts General Hospital

Start Date

2/3/2025

Completion Date

4/1/2028

Summary

In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.

Eligibility Criteria

Age Range: 45 years to No maximum

Inclusion Criteria: * women aged 45+ * postmenopausal * osteoporotic with high risk of fracture Exclusion Criteria: * no significant previous use of bone health modifying treatments * known congenital or acquired bone disease other than osteoporosis * significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease * abnormal calcium or parathyroid hormone level * serum vitamin D \<20 ng/dL * anemia (hematocrit \<32%) * history of malignancy (except non-melanoma skin carcinoma) * excessive alcohol use or substance abuse * known contraindications to romosozumab or teriparatide

Interventions

DRUG

Romosozumab

DRUG

Teriparatide

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Osteoporosis, PostmenopausalOsteoporosis

Locations

Massachusetts General Hospital

Boston, Massachusetts 02114

United States